|
31 Mar 2020 |
I-Mab Submits IND Application to Initiate Study of TJM2 for Treatment of Cytokine Storm Associated with Severe COVID-19 in South Korea
|
|
31 Mar 2020 |
GigaGen Initiates Development of Recombinant Polyclonal Antibody Therapy for COVID-19
|
|
31 Mar 2020 |
Mersana Therapeutics Reports Updated Data from the XMT-1536 Phase 1 Dose Escalation Study
|
|
30 Mar 2020 |
Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
|
|
30 Mar 2020 |
First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19
|
|
30 Mar 2020 |
Imfinzi approved in the US for extensive-stage small cell lung cancer
|
|
30 Mar 2020 |
Mylan and Lupin Announce Positive CHMP Opinion for Nepexto®, Biosimilar Etanercept
|
|
29 Mar 2020 |
Novartis Cosentyx® gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum
|
|
27 Mar 2020 |
Sanofi receives positive CHMP opinion for Sarclisa® (isatuximab) for the treatment of relapsed and refractory multiple myeloma
|
|
27 Mar 2020 |
Bolt Biotherapeutics Announces Initiation of BDC-1001 Clinical Trial in Patients with HER2-Expressed Solid Tumors
|
|
26 Mar 2020 |
First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta T Cell-Activating Immunotherapy
|
|
26 Mar 2020 |
Eisai submits marketing authorization application in Japan for anticancer agent denileukin diftitox (genetic recombinant) for cutaneous T-cell lymphoma and peripheral T-cell lymphoma
|
|
26 Mar 2020 |
Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend XmAb Antibody Technology in Investigational Antibodies to Treat COVID-19
|
|
26 Mar 2020 |
Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19
|
|
25 Mar 2020 |
ENHERTU® Approved in Japan for Treatment of Patients with HER2 Positive Unresectable or Metastatic Breast Cancer
|
|
25 Mar 2020 |
Allakos Announces the Initiation of Antolimab (AK002) Clinical Studies
|
|
24 Mar 2020 |
Aravive Announces Initiation of Investigator-Sponsored Phase 1/2 Study of AVB-500 in Combination with Avelumab in Patients with Advanced Urothelial Carcinoma (COAXIN)
|
|
24 Mar 2020 |
Sorrento collaborates with Mabpharm on development and commercialization of ACE-MAB™ to potentially treat COVID-19
|
|
23 Mar 2020 |
Celltrion Accelerates Development of COVID-19 Antiviral Treatment and Aims to Launch Rapid Self-testing Kit
|
|
23 Mar 2020 |
Genentech Announces FDA Approval of Clinical Trial for Actemra to Treat Hospitalized Patients With Severe COVID-19 Pneumonia
|
|
20 Mar 2020 |
Sorrento develops STI-4398 (COVIDTrap™ protein) for potential prevention and treatment of SARS-Cov-2 coronavirus disease (COVID-19)
|
|
20 Mar 2020 |
Junshi Biosciences Announces Co-Development Agreement with IMCAS to Advance Neutralizing Antibodies as Potential Novel Treatment for COVID-19
|
|
19 Mar 2020 |
Genentech Initiates Phase III Clinical Trial Of Actemra In Hospitalized Patients With Severe COVID-19 Pneumonia
|
|
19 Mar 2020 |
Roivant Announces Development of Anti-GM-CSF Monoclonal Antibody to Prevent and Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19
|
|
18 Mar 2020 |
Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Candidate SRF617
|
